$0.31 EPS Expected for LCNB Corp. (LCNB); 2 Analysts Are Bullish Spectrum Pharmaceuticals, Inc. (SPPI) Last Week

July 17, 2017 - By Peter Erickson

Analysts expect LCNB Corp. (NASDAQ:LCNB) to report $0.31 EPS on July, 18.They anticipate $0.02 EPS change or 6.90% from last quarter’s $0.29 EPS. LCNB’s profit would be $3.09M giving it 16.33 P/E if the $0.31 EPS is correct. After having $0.32 EPS previously, LCNB Corp.’s analysts see -3.13% EPS growth. The stock decreased 0.74% or $0.15 on July 14, reaching $20.25. About shares traded. LCNB Corp. (NASDAQ:LCNB) has risen 17.18% since July 17, 2016 and is uptrending. It has outperformed by 0.48% the S&P500.

Among 2 analysts covering Spectrum Pharma (NASDAQ:SPPI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharma had 5 analyst reports since August 7, 2015 according to SRatingsIntel. On Friday, February 10 the stock rating was maintained by Jefferies with “Buy”. The rating was upgraded by Zacks to “Hold” on Thursday, August 27. The firm has “Outperform” rating given on Thursday, November 5 by RBC Capital Markets. Jefferies maintained it with “Buy” rating and $900 target in Wednesday, June 7 report. RBC Capital Markets maintained Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rating on Friday, August 7. RBC Capital Markets has “Outperform” rating and $13 target. See Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) latest ratings:

07/06/2017 Broker: Jefferies Rating: Buy New Target: $9.0000 Maintain
10/02/2017 Broker: Jefferies Old Rating: Hold New Rating: Buy Maintain

Since February 13, 2017, it had 0 buys, and 5 selling transactions for $437,194 activity. McKay Leroy F also sold $36,115 worth of LCNB Corp. (NASDAQ:LCNB) shares. Haines Robert C II had sold 275 shares worth $6,078 on Monday, February 27. 15,333 LCNB Corp. (NASDAQ:LCNB) shares with value of $305,156 were sold by WILSON STEPHEN P.

LCNB Corp. is a financial holding company. The company has market cap of $202.08 million. The Company’s subsidiary includes LCNB National Bank (the Bank). It has a 15.78 P/E ratio. The Bank offers commercial and personal banking services.

Investors sentiment decreased to 1.61 in 2016 Q4. Its down 0.02, from 1.63 in 2016Q3. It dropped, as 4 investors sold LCNB Corp. shares while 14 reduced holdings. 9 funds opened positions while 20 raised stakes. 2.86 million shares or 6.98% more from 2.67 million shares in 2016Q3 were reported. 89,300 were accumulated by Renaissance Tech Limited Liability. Jpmorgan Chase owns 13,412 shares. Bartlett Lc has 3,800 shares. Moreover, Bessemer Gru has 0% invested in LCNB Corp. (NASDAQ:LCNB) for 7,200 shares. Ameriprise Inc holds 0% of its portfolio in LCNB Corp. (NASDAQ:LCNB) for 12,115 shares. California Pub Employees Retirement Sys, a California-based fund reported 20,700 shares. Fmr Limited Liability Corp accumulated 0% or 761,755 shares. Legal & General Grp Incorporated Public Ltd Co has invested 0% in LCNB Corp. (NASDAQ:LCNB). Blackrock invested 0% in LCNB Corp. (NASDAQ:LCNB). New York State Common Retirement Fund holds 0% or 9,100 shares. Susquehanna Intl Group Llp holds 0% of its portfolio in LCNB Corp. (NASDAQ:LCNB) for 10,145 shares. Bnp Paribas Arbitrage owns 451 shares for 0% of their portfolio. Bahl Gaynor holds 0% or 13,673 shares. Finance Gp has 0.24% invested in LCNB Corp. (NASDAQ:LCNB). Geode Mgmt Llc has invested 0% of its portfolio in LCNB Corp. (NASDAQ:LCNB).

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The company has market cap of $607.12 million. The Firm operates through developing and commercializing oncology and hematology drug products segment. It currently has negative earnings. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: